Advanced imaging reveals how childhood brain tumours grow and spread
Researchers at The Institute of Cancer Research, London, led work to develop a large panel of patient-derived mouse models of paediatric-type diffuse high-grade glioma (PDHGG) – a group of brain tumours with poor survival rates. Using magnetic resonance imaging (MRI), the research team demonstrated that these models reproduce key biological and radiological features of the human disease. Read more: https://www.icr.ac.uk/about-us/icr-news/detail/advanced-imaging-reveals-how-ch
Mar 11
Three Childhood Cancers Have a Shared Dependence on Light-Sensing Genes
Research uncovering the origin of pineoblastoma, a rare pediatric brain tumor, has also revealed a dependency across multiple brain tumor types that share a similar molecular program. Read more: https://www.technologynetworks.com/tn/news/three-childhood-cancers-have-a-shared-dependence-on-light-sensing-genes-410398
Mar 10
Hearing loss contributes to cognitive decline after childhood cancer treatment
Research from St. Jude led by Heather Conklin, PhD, Department of Psychology & Biobehavioral Sciences, demonstrated that radiation therapy was a significant individual contributor to hearing loss, a risk directly linked to cognitive health, in children treated for ependymoma. Read more: https://www.eurekalert.org/news-releases/1117443
Feb 25
Discovery of unique brain tumor subtypes offers hope for targeted glioma therapies
Researchers have uncovered the mechanisms behind three unique subtypes of mismatch repair deficient high-grade gliomas. The findings provide a clearer understanding of how these tumors develop, explain why patients respond differently to immunotherapy, and are already helping guide more precise therapies. Read more: https://medicalxpress.com/news/2026-02-discovery-unique-brain-tumor-subtypes.html
Feb 13
Itaconate identified as a new target for pediatric brain tumors called ependymomas
In a study published in Nature , University of Michigan researchers have found that a specific molecule called itaconate drives the development of ependymomas. Their findings can help future drug development for children with this type of malignant brain tumor. Read more: https://www.michiganmedicine.org/health-lab/itaconate-identified-new-target-pediatric-brain-tumors-called-ependymomas
Feb 10
Children with brain cancer given hope in trial of personalised vaccines across eight Australian hospitals
A world-first trial of a personalised vaccine for children with deadly brain cancers will be rolled out in eight hospitals throughout Australia later this year. Read more: https://www.abc.net.au/news/2026-02-03/brain-cancer-vaccine-trial-for-children/106294532
Feb 6
Revolutionary genome mapping tech targets childhood brain cancers
A new research collaboration aims to transform the treatment of children with brain tumors by identifying hidden genetic drivers that current diagnostic technologies often miss. Read more: https://jagwire.augusta.edu/revolutionary-genome-mapping-tech-targets-childhood-brain-cancers/
Jan 30
New Human Brain Model For Deadly Childhood Brain Cancer
Researchers at Oncode Institute and Princess Máxima Center have developed a new human model of the brainstem that is changing how one of the most aggressive childhood brain cancers can be studied. Read more: https://www.zonmw.nl/en/news/new-human-brain-model-deadly-childhood-brain-cancer
Jan 23
Dual therapy shows promise for childhood brain cancer
In a new study, Children’s Cancer Institute and UNSW Sydney researchers lab-tested a combined therapy approach on a group of difficult-to-treat brain tumours: diffuse midline gliomas (DMG). This group includes diffuse intrinsic pontine glioma (DIPG), a rare but fatal childhood brain cancer. Read more: https://www.unsw.edu.au/newsroom/news/2026/01/dual-therapy-shows-promise-for-childhood-brain-cancer
Jan 20
Unique statistical approach lends promise to therapies for rare childhood brain cancer
Researchers at the University of Louisville used a modern statistical method to reanalyze the results of children with a special type of high-risk medulloblastoma called Group 3, who participated in two major national clinical trials of therapies. Read more: https://www.uoflnews.com/section/science-and-tech/unique-statistical-approach-lends-promise-to-therapies-for-rare-childhood-brain-cancer/
Jan 19

